Natco Pharma Ltd (NATCOPHARM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524816 | NSE: NATCOPHARM | Pharmaceuticals & Drugs | Small Cap

Natco Pharma Share Price

934.15 -14.70 -1.55%
as on 05-Dec'25 15:23

Natco Pharma Ltd (NATCOPHARM) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 524816 | NSE: NATCOPHARM | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Natco Pharma

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Natco Pharma stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
11.04
Market Cap:
16,994.8 Cr.
52-wk low:
660.1
52-wk high:
1,504

Is Natco Pharma Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Natco Pharma: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Natco Pharma Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 17.5%39.2%35.3%23.7%14.8%14%4.9%18.1%30.1%32.9%-
Value Creation
Index
0.31.91.60.80.10.0-0.60.31.21.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,0422,0202,1852,0951,9152,0521,9452,7073,9994,4304,388
Sales YoY Gr.-93.8%8.2%-4.1%-8.6%7.2%-5.2%39.2%47.7%10.8%-
Adj EPS 927.737.233.924.522.87.337.977.1100.385.9
YoY Gr.-209%34.4%-9%-27.7%-6.9%-68.1%420.6%103.3%30.2%-
BVPS (₹) 73.993.6165.2189.5206224.9233.4267.1327425482.9
Adj Net
Profit
1564836876194464161336921,3801,7961,539
Cash Flow from Ops. 11234646466941729946.58491,2121,697-
Debt/CF from Ops. 10.60.40.60.80.98.70.20.30.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 17.4%18.3%31.6%10.8%
Adj EPS 30.8%32.6%139.7%30.2%
BVPS21.5%15.6%22.1%30%
Share Price 6.5% 0.3% 17.3% -35.2%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
14.632.829.118.912.310.53.215.125.726.718.9
Op. Profit
Mgn %
25.933.842.538.130.429.413.633.943.949.539.6
Net Profit
Mgn %
14.823.831.429.523.120.36.825.534.540.535.1
Debt to
Equity
0.10.10.10.10.10.10.100.100
Working Cap
Days
230169252315381374339278210221212
Cash Conv.
Cycle
79517696124152179145102105167

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Natco Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 84.8 85.9
TTM Sales (₹ Cr.) 4,022 4,388
BVPS (₹.) 461.8 482.9
Reserves (₹ Cr.) 8,235 8,614
P/BV 2.05 1.96
PE 11.20 11.04
From the Market
52 Week Low / High (₹) 660.05 / 1504.00
All Time Low / High (₹) 1.60 / 1638.35
Market Cap (₹ Cr.) 16,995
Equity (₹ Cr.) 35.8
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Natco Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Natco Pharma - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Natco Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales1,0422,0202,1852,0951,9152,0521,9452,7073,9994,430
Operating Expenses 7771,3371,2561,3001,3321,4481,6811,7952,2472,236
Manufacturing Costs149220239336306353430362457468
Material Costs271599411333354484528583668642
Employee Cost 180243326356375415445487525595
Other Costs 177274281275297197278364597532
Operating Profit 2666839287955836042649121,7512,194
Operating Profit Margin (%) 25.5%33.8%42.5%37.9%30.4%29.4%13.5%33.7%43.8%49.5%
Other Income 10144013010710699129128357
Interest 23191519221318151924
Depreciation 51546681100117143164187235
Exceptional Items 0000000000
Profit Before Tax 2026248878255695802028621,6742,291
Tax 4814019218211113732147285408
Profit After Tax 1544856956424584421707151,3881,883
PAT Margin (%) 14.7%24.0%31.8%30.7%23.9%21.6%8.7%26.4%34.7%42.5%
Adjusted EPS (₹)9.027.937.735.325.324.29.339.277.6105.3
Dividend Payout Ratio (%)14%24%22%18%27%22%48%14%12%6%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 1,2861,6343,0483,4583,7504,1044,2604,8745,8537,607
Share Capital 35353737363737373636
Reserves 1,2511,5993,0113,4223,7144,0684,2244,8375,8177,571
Minority Interest54421120005
Debt98222173386314266404165363273
Long Term Debt0000000000
Short Term Debt98222173386314266404165363273
Trade Payables276263269217255146162264236275
Others Liabilities 157195221240257274283355435420
Total Liabilities 1,8222,3183,7154,3034,5884,7925,1095,6576,8878,581

Fixed Assets

Gross Block9831,1591,4081,6952,1492,7023,1273,3753,6034,015
Accumulated Depreciation2733263894675646798159481,1121,267
Net Fixed Assets 7108331,0191,2271,5842,0232,3122,4272,4912,748
CWIP 21233648063851822313064137225
Investments 223277169112304308392539474
Inventories357349438529558798762743701766
Trade Receivables2624756385065514136218561,1891,247
Cash Equivalents 4536184280662842065469532,176
Others Assets 2142568809551,198747771629877945
Total Assets 1,8222,3183,7154,3034,5884,7925,1095,6576,8878,581

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 112346464669417299478491,2121,697
PBT 2096248878255695802028621,6742,291
Adjustment 9110076145462124102134-22
Changes in Working Capital -141-253-2959-98-213-23163-309-200
Tax Paid -46-126-205-179-108-130-48-178-286-373
Cash Flow From Investing Activity -176-299-1,116-612-167-103-5-477-1,033-1,415
Capex -138-280-407-444-337-207-179-116-357-397
Net Investments -18-17-569-130-12736226-410-736-1,168
Others -19-3-140-3929668-534960150
Cash Flow From Financing Activity 154-48651-51-251-18635-363-247-211
Net Proceeds from Shares 33408960000007
Net Proceeds from Borrowing -129-1400000000
Interest Paid -26-16-16-19-22-13-17-14-18-18
Dividend Paid -26-141-181-92-154-114-82-100-171-108
Others 1124-4860-75-59134-248-58-93
Net Cash Flow 91-1-16-110769-6872

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)14.4133.2129.719.7512.7111.274.0615.6625.8827.98
ROCE (%)17.4939.2135.2823.7114.8213.994.8618.0630.0832.85
Asset Turnover Ratio0.6710.730.570.460.440.450.540.690.62
PAT to CFO Conversion(x)0.730.710.671.040.910.680.281.190.870.9
Working Capital Days
Receivable Days77659291948485948693
Inventory Days9862657796119128956156
Payable Days270164236267243152106133136145

Natco Pharma Ltd Stock News

Natco Pharma Ltd FAQs

The current trading price of Natco Pharma on 05-Dec-2025 15:23 is ₹934.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Natco Pharma stood at ₹16,994.8.
The latest P/E ratio of Natco Pharma as of 04-Dec-2025 is 11.20.
The latest P/B ratio of Natco Pharma as of 04-Dec-2025 is 2.05.
The 52-week high of Natco Pharma is ₹1,504 and the 52-week low is ₹660.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Natco Pharma is ₹4,022 ( Cr.) .

About Natco Pharma Ltd

Natco Pharma was promoted by V C Nannapaneni in the year 1981 as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh. The company focus is primarily on niche therapeutic areas and complex products. It market and distribute products in various countries. It also operates in certain key geographies through its subsidiaries.

Natco Pharma manufactures API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets. In the API segment, company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.

Business area of the company

Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). It is also engaged in contract manufacturing business, whereby it undertake selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. It has diversified into the business of crop health sciences to leverage is skills in organic chemistry.

Products:

  • Formulations
  • API’s
  • Contract manufacturing
  • Crop Health Sciences

Milestone:

  • 1981: Incorporated Natco Pharma Division at Kothur, Mahaboobnagar Dist, Telangana, India.
  • 1984: First full year in operation- sales of Rs 0.5 million
  • 1986: Inaugurated parental manufacturing facility at Nagarjunasagar, Telangana, India.
  • 1993: Inaugurated Natco’s chemical division at Mekaguda in Telangana.
  • 1995: Natco trust was founded. Natco merged three of groups companies with the parent company.
  • 1997: Inaugurated Natco Research Center (NRC) at Sanathnagar, Hyderabad, India.
  • 2003: Launched Oncology division with introduction of the flagship brand VEENAT (generic Imatinib Mesylate) for the treatment of chronic myelogenous leukemia.
  • 2006: Incorporated a finished dosage facility at Dehradun, Uttrakhand.
  • 2007: Natco launched its first ever ANDA in the US market. Natco acquired Savemart Pharmacy in USA.
  • 2008: Natco filed its first paragraph IV filing in the US market.
  • 2009: Inaugurated Natco Organics at Chennai, India with facilities dedicated for Cyto-toxic APIS’s Biotechnology products. Natco’s turnover reached $100 million.
  • 2011: Incorporated Natcofarma do Brazil LTDA.
  • 2012: Compulsory License was granted by government of India for patent protected anti-cancer drug Nexavar of Bayer.
  • 2012: Established Natco Pharma Asia Pte Ltd for sales and distribution in Singapore and winner of Golden peacock award for CSR work.
  • 2013: Established Natco Pharma Canada Inc for sales and distribution in Canada.
  • 2014: Established Natco Pharma Australia Pty Ltd for sales and distribution in Australia.
  • 2016: Sold U.S. based Save Mart pharmacy store. 
  • 2016: Winner of 'Golden Peacock Environment Management Award' for the Year 2016.
  • 2016: Launched generic version of Oseltamivir Phosphate capsules in the United States.
  • 2017: Started Cardiology and Diabetology divisions for domestic market with launches like Dabigatran. 
  • 2017: Launched Glatiramer Acetate injection (20 & 40 mg/ml) in the US. 
  • 2017: Launched complex drug delivery product, liposomal doxorubicin in the US.
  • 2018: USFDA completed inspection of Natco’s Mekaguda API facility with zero observations. 
  • 2018: Natco launched its first generic version of oral tablets Teriflunomide for Multiple Sclerosis in India. 
  • 2018: Natco introduced generic Posaconazole injection, available for the first time in India.
  • 2019: Commercial manufacturing operations begin in NATCO's Visakhapatnam Formulation Facility. 
  • 2019: Natco launches Crop Health Sciences Division.
  • 2019: Natco Pharma invests Rs 5 crore in OMRV Hospitals.
  • 2019: Natco Pharma has commenced commercial operations at Finished Dosage Formulations (FDF) facility in Visakhapatnam.
  • 2020: Natco Pharma’s subsidiary -- Natco Pharma (Canada) Inc., has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada. The terms of the agreement are confidential as per the agreement.
  • 2020: Natco Pharma has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam (Vizag) Andhra Pradesh, India.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×